Obstructive sleep apnea and chronic heart failure


DOI: https://dx.doi.org/10.18565/therapy.2022.1.35-43

Bolieva L.Z., Adasheva T.V., Malyavin A.G., Bichenova E.R., Daurova M.D.

1) North Ossetian State Medical Academy of the Ministry of Healthcare of Russia, Vladikavkaz; 2) A.I. Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia
Abstract. Effective treatment of chronic heart failure (CHF) is one of the most important problems of modern healthcare. The results of CHF therapy largely depend on the timely and successful diagnosis and treatment of concomitant pathology. One of the most common comorbid pathologies among patients with CHF are sleep breathing disorders, in particular obstructive sleep apnea syndrome (OSAS). The article presents currently available data on the relationship between OSAS and CHF. Such key aspects as the prevalence, pathogenesis, course and prognosis of comorbidity of CHF with OSA, improvement of treatment of this category of patients are discussed. It also justifies the need for further research to improve approaches to the management of patients with CHF and OSAS.
Keywords: sleep-disordered breathing, CPAP therapy, obstructive sleep apnea syndrome, chronic heart failure
Read entire article

Literature


  1. Шляхто Е.В., Звартау Н. Э., Виллевальде С.В. с соавт. Система управления сердечно-сосудистыми рисками: предпосылки к созданию, принципы организации, таргетные группы. Российский кардиологический журнал. 2019; 11: 69–82. [Shlyakhto E.V., Zvartau N.E., Villevalde S.V. et al. Cardiovascular risk management system: prerequisites for developing, organization principles, target groups. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2019; 11: 69–82 (In Russ.)]. http://dx.doi.org/10.15829/1560-4071-2019-11-69-82.

  2. New WHO report: population-based screening for cardiovascular disease risk factors does not reduce CVD mortality. URL: https://www.euro.who.int/en/health-topics/noncommunicable-diseases/cardiovascular-diseases/news/news/2021/01/new-who-report-population-based-screening-for-cardiovascular-disease-risk-factors-does-not-reduce-cvd-mortality (date of access – 11.01.2022).

  3. Snipelisky D., Chaudhry S.P., Stewart G.C. The many faces of heart failure. Сard Electrophysiol Clin. 2019; 11(1): 11–20. http://dx.doi.org/10.1016/j.ccep.2018.11.001.

  4. Ceriello A., Catrinoiu D., Chandramouli C. et al. Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management. Cardiovasc Diabetol. 2021; 20(1): 218. http://dx.doi.org/10.1186/s12933-021-01408-1.

  5. Виллевальде С.В., Соловьева А.Е., Звартау Н.Э. с соавт. Принципы организации медицинской помощи пациентам с сердечной недостаточностью в системе управления сердечно-сосудистыми рисками: фокус на преемственность и маршрутизацию пациентов. Практические материалы. Российский кардиологический журнал. 2021; 26(S3): 4558. [Villevalde S. V., Soloveva A. E., Zvartau N. E. et al. Principles of organization of medical care for patients with heart failure in the system of cardiovascular risk management: focus on continuity of care and patient routing. Practical materials. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2021; 26(S3): 4558. (In Russ.)]. http://dx.doi.org/10.15829/1560-4071-2021-4558.

  6. Suciadi L.P., Wibawa K., Jessica G. et al. Tachycardia and pre-existing chronic kidney disease are predictors of the worse clinical outcomes in patients recently hospitalized with acute heart failure. Cureus. 2021; 13(6): e15802. http://dx.doi.org/10.7759/cureus.15802.

  7. Groenewegen A., Rutten F.H., Mosterd A. et al. Epidemiology of heart failure. Eur J Heart Fail. 2020; 22(8): 1342–56. http://dx.doi.org/10.1002/ejhf.1858.

  8. Муртазалиева П.М., Карелкина Е.В., Шишкова А.А. с соавт. Пилотный проект «Совершенствование медицинской помощи больным хронической сердечной недостаточностью»: результаты I этапа. Российский кардиологический журнал. 2018; 2: 44–50. [Murtazalieva P.M., Karelkina E.V., Shishkova A.A. et al. Pilot project «Improvement of medical care for patients with chronic heart failure»: results of the first stage. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2018; 12: 44–50 (In Russ.)] http://dx.doi.org/10.15829/1560-4071-2018-12-44-50.

  9. Shah K.S., Xu H., Matsouaka R.A. et al. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol. 2017; 70(20): 2476–86. https://dx.doi.org/10.1016/j.jacc.2017.08.074.

  10. Фомин И.В. Хроническая сердечная недостаточность в Российской Федерации: что сегодня мы знаем и что должны делать. Российский кардиологический журнал. 2016; 8: 7–13. [Fomin I.V. Chronic heart failure in Russian Federation: what do we know and what to do. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2016; 8: 7–13 (In Russ.)]. https://dx.doi.org/10.15829/1560-4071-2016-8-7-13.

  11. Поляков Д.С., Фомин И.В., Беленков Ю.Н. с соавт. Хроническая сердечная недостаточность в Российской Федерации: что изменилось за 20 лет наблюдения? Результаты исследования ЭПОХА-ХСН. Кардиология. 2021; 4: 4–14. [Polyakov D.S., Fomin I.V., Belenkov Yu.N. et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study. Kardiologiya = Cardiology. 2021; 4: 4–14 (In Russ.)]. https://dx.doi.org/10.18087/cardio.2021.4.n1628.

  12. Crespo-Leiro M.G., Anker S.D., Maggioni A.P. et al. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur J Heart Fail. 2016; 18(6); 613–25. https://dx.doi.org/10.1002/ejhf.566.

  13. Виноградова Н.Г., Поляков Д.С., Фомин И.В. Анализ смертности у пациентов с ХСН после декомпенсации при длительном наблюдении в условиях специализированной медицинской помощи и в реальной клинической практике. Кардиология. 2020; 4: 91–100. [Vinogradova N.G., Polyakov D.S., Fomin I.V. Analysis of mortality in patients with heart failure after de­compen­sation during long-term follow-up in specialized medical care and in real clinical practice. Kardiologiya = Cardiology. 2020; 4: 91–100 (In Russ.)]. https://dx.doi.org/10.18087/cardio.2020.4.n1014.

  14. Bozkurt B., Coats A.J.S., Tsutsui H. et al. Universal definition and classification of heart failure: A report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail. 2021; 23(3): 352–80. https://dx.doi.org/10.1002/ejhf.2115.

  15. Vecchi A.L., Muccioli S., Marazzato J. et al. Prognostic role of subclinical congestion in heart failure outpatients: focus on right ventricular dysfunction. J Clin Med. 2021; 10(22): 5423. https://dx.doi.org/10.3390/jcm10225423.

  16. McDonagh T.A., Metra M., Adamo M. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42(36): 3599–726. https://dx.doi.org/10.1093/eurheartj/ehab368.

  17. Российское кардиологическое общество (РКО). Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020; 11: 4083. [Russian Society of Cardiology (RSC). 2020. Clinical practice guidelines for chronic heart failure. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2020; 11: 4083 (In Russ.)]. https://dx.doi.org/10.15829/1560-4071-2020-4083.

  18. Bughin F., Jaussent I., Ayoub B. et al. Prognostic impact of sleep patterns and related-drugs in patients with heart failure. J Clin Med. 2021; 10(22): 5387. https://dx.doi.org/10.3390/jcm10225387.

  19. Comin-Colet J., Lorenzo T.M., Gonzalez-Domínguez A. et al. Impact of non-cardiovascular comorbidities on the quality of life of patients with chronic heart failure: a scoping review. Health Qual Life Outcomes. 2020; 18(1): 329. https://dx.doi.org/10.1186/s12955-020-01566-y.

  20. Крупичка К.С., Агальцов М.В., Мясников Р.П. с соавт. Нарушения дыхания во сне у пациентов с хронической сердечной недостаточностью: классификация, эпидемиология и патофизиология. Часть I. Российский кардиологический журнал. 2021; 2S: 4386. [Krupichka K.S., Agaltsov M.V., Myasnikov R.P. Sleep-related breathing disorders in patients with heart failure: classification, epidemiology and pathophysiology. Part I. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2021; 2S: 4386 (In Russ.)]. https://dx.doi.org/10.15829/1560-4071-2021-4386.

  21. Бузунов Р.В., Пальман А.Д., Мельников А.Ю. с соавт. Диагностика и лечение синдрома обструктивного апноэ сна у взрослых. Рекомендации Российского общества сомнологов (РОС). Эффективная фармакотерапия. 2018; 35: 34–45. [Buzunov R.V., Palman A.D., Melnikov A.Yu. et al. DIagnostics and treatment of obstructive sleep apnea syndrome in adults. recommendations of The Russian Society of Sleep Medicine. Effektivnaya farmakoterapiya = Effective Pharmacotherapy. 2018; 35: 34–45 (In Russ.)].

  22. Laratta C.R., Ayas N.T., Povitz M. et al. Diagnosis and treatment of obstructive sleep apnea in adult. CMAJ. 2017; 189(48): E1481–88. https://dx.doi.org/10.1503/cmaj.170296.

  23. Лышова О.В., Костенко И.И. Предикторы синдрома обструктивного апноэ сна по данным клинического исследования и результатам суточного мониторирования артериального давления. Кардиология. 2018; 9: 12–20. [Lyshova O.V., Kostenko I.I. Predictors of obstructive sleep apnea syndrome according to results of clinical examination and ambulatory blood pressure monitoring. Kardiologiya = Cardiology. 2018; 9: 12–20 (In Russ.)]. https://dx.doi.org/10.18087/cardio.2018.9.10169.

  24. Елфимова Е.М., Михайлова О.О., Хачатрян Н.Т. с соавт. Клинический профиль пациентов с синдромом обструктивного апноэ сна в кардиологическом стационаре. Терапевтический архив. 2020; 4: 9–16. [Elfimova E.M., Mikhailova O.O., Khachatryan N.T.et al. Clinical profile of patients with obstructive sleep apnea syndrome in a cardiology hospital. Terapevticheskiy arkhiv = Therapeutic Archive. 2020; 4: 9–16 (In Russ.)]. https://dx.doi.org/10.26442/00403660.2020.04.000553.

  25. Collen J., Lettieri C., Wickwire E. et al. Obstructive sleep apnea and cardiovascular disease, a story of confounders! Sleep Breath. 2020; 24 (4): 1299–313. https://dx.doi.org/10.1007/s11325-019-01945-w.

  26. Магомедова Н.М., Голухова Е.З. Слип-апноэ и сердечно-сосудистые риски. Креативная кардиология. 2016; 3: 201–209. [Magomedova N.M., Golukhova E.Z. Obstructive sleep apnea and the risk of cardiovascular disease. Kreativnaya kardiologiya = Creative Cardiology. 2016; 3: 201–209 (In Russ.)]. https://dx.doi.org/10.15275/kreatkard.2016.03.03.

  27. Khattak H.K., Hayat F., Pamboukian S.V. et al. Obstructive sleep apnea in heart failure: Review of prevalence, treatment with continuous positive airway pressure, and prognosis. Tex Heart Inst J. 2018; 45(3): 151–61. https://dx.doi.org/10.14503/THIJ-15-5678.

  28. Nakamura M., Sadoshima J. Mechanisms of physiological and pathological cardiac hypertrophy. Nat Rev Cardiol. 2018; 15(7): 387–407. https://dx.doi.org/10.1038/s41569-018-0007-y.

  29. Гриценко О.В., Чумакова Г.А., Шевляков И.В. с соавт. Внеклеточный матрикс сердца и его изменения при фиброзе миокарда. Кардиология. 2020; 6: 107–112. [Gritsenko O.V., Chumakova G.A., Shevlyakov I.V. et al. Extracellular matrix of the heart and its changes in myocardial fibrosis. Kardiologiya = Cardiology. 2020; 6: 107–112 (In Russ.)]. https://dx.doi.org/10.18087/cardio.2020.6.n773.

  30. Заболотских И.Б., Трембач Н.В. Прогностическая роль чувствительности барорефлекса в оценке периоперационного риска. Вестник интенсивной терапии имени А.И. Салтанова. 2020; 2: 49–62. [Zabolotskikh I.B., Trembach N.V. Predictive role of baroreflex sensitivity in the assessment of perioperative risk. Vestnik intensivnoy terapii imeni A.I. Saltanova = A.I. Saltanov Annals of Critical Care. 2020; 2: 49–62 (In Russ.)]. https://dx.doi.org/10.21320/1818-474X-2020-2-49-62.

  31. Peker Y., Balcan B. Cardiovascular outcomes of continuous positive airway pressure therapy for obstructive sleep apnea. J Thorac Dis. 2018; 10(Suppl 34): S4262–S4279. https://dx.doi.org/10.21037/jtd.2018.11.48.

  32. Haruki N., Floras J.S. Sleep-disordered breathing in heart failure – a therapeutic dilemma. Circ J. 2017; 81(7): 903–12. https://dx.doi.org/10.1253/circj.CJ-17-0440.

  33. Huang Y., Wang Y., Huang Y. et al. Prognostic value of sleep apnea and nocturnal hypoxemia in patients with decompensated heart failure. Clin Cardiol. 2020; 43(4): 329–37. https://dx.doi.org/10.1002/clc.23319.

  34. Xie J., Kuniyoshi F.H.S., Covassin N. et al. Nocturnal hypoxemia due to obstructive sleep apnea is an independent predictor of poor prognosis after myocardial infarction. J Am Heart Assoc. 2016; 5(8): e003162. https://dx.doi.org/10.1161/JAHA.115.003162.

  35. Arzt M., Woehrle H., Oldenburg O. et al. Prevalence and predictors of sleep-disordered breathing in patients with stable chronic heart failure: The SchlaHF Registry. JACC Heart Fail. 2016; 4(2): 116–25. https://dx.doi.org/10.1016/j.jchf.2015.09.014.

  36. Бочкарев М.В., Коростовцева Л.С., Фильченко И.А. с соавт. Жалобы на нарушения дыхания во сне и факторы риска сердечно-сосудистых заболеваний в регионах России: данные исследования ЭССЕ-РФ. Российский кардиологический журнал. 2018; 6: 152–158. [Bochkarev M.V., Korostovtseva L.S., Filchenko I.А. et al. Complaints on sleep breathing disorders and cardiovascular risk factors in Russian regions: data from ESSE-RF study. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2018; 6: 152–158 (In Russ.)]. https://dx.doi.org/10.15829/1560-4071-2018-6-152-158.

  37. Yamaguchi T., Takata Y., Usui Y. et al. Nocturnal intermittent hypoxia is associated with left ventricular hypertrophy in middle-aged men with hypertension and obstructive sleep apnea. Am J Hypertens. 2016; 29(3): 372–78. https://dx.doi.org/10.1093/ajh/hpv115.

  38. Литвин А.Ю., Михайлова О.О., Елфимова Е.М. с соавт. Синдром обструктивного апноэ сна и сердечно-сосудистые события. Consilium Medicum. 2016; 1: 83–87. [Litvin A.Yu., Mikhailova O.O., Elfimova E.M. et al. Obstructive sleep apnea syndrome and cardiovascular events. Consilium Medicum. 2016; 1: 83–87. (In Russ.)]. https://dx.doi.org/10.26442/2075-1753_2016.1.83-87.

  39. Бродовская Т.О., Грищенко О.О., Гришина И.Ф. с соавт. Особенности ремоделирования сердца у пациентов с синдромом обструктивного апноэ сна и его коморбидной ассоциацией с ожирением в контексте концепции раннего старения. Российский кардиологический журнал. 2019; 4: 27–34. [Brodovskaya T.O., Grishchenko O.O., Grishina I.F. et al. Features of heart remodeling in patients with obstructive sleep apnea syndrome and its comorbid association with obesity in the context of the senilism concept. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2019; 4: 27–34 (In Russ.)]. https://dx.doi.org/10.15829/1560-4071-2019-4-27-34.

  40. Hla K.M., Young T., Hagen E.W. et al. Coronary heart disease incidence in sleep disordered breathing: the Wisconsin Sleep Cohort Study. Sleep. 2015; 38(5): 677–84. https://dx.doi.org/10.5665/sleep.4654.

  41. Salman L.A., Shulman R., Cohen J.B. Obstructive sleep apnea, hypertension, and cardiovascular risk: Epidemiology, pathophysiology, and management. Curr Cardiol Rep. 2020; 22(2): 6. https://dx.doi.org/10.1007/s11886-020-1257-y.

  42. Rotenberg B.W., Murariu D., Pang K.P. Trends in CPAP adherence over twenty years of data collection: A flattened curve. J Otolaryngol Head Neck Surg. 2016; 45(1): 43. https://dx.doi.org/10.1186/s40463-016-0156-0.

  43. McEvoy R.D., Antic N.A., Heeley E. et al. CPAP for prevention of cardiovascular events in obstructive sleep apnea. N Engl J Med. 2016; 375(10): 919–31. https://dx.doi.org/10.1056/NEJMoa1606599.

  44. Furlow B. SAVE trial: No cardiovascular benefits for CPAP in OSA. Lancet Respir Med. 2016; 4(11): 860. https://dx.doi.org/10.1016/S2213-2600(16)30300-9.

  45. Горбунова М.В., Бабак С.Л., Малявин А.Г. Динамика метаболических нарушений у пациентов с обструктивным апноэ сна в зависимости от продолжительности СРАР-терапии. Лечебное дело. 2019; 2: 64–69. [Gorbunova M.V., Babak S.L., Malyavin A.G. The dynamics of metabolic disorders in patients with obstructive sleep apnea depending on duration of CPAP therapy. Lechebnoe delo = General Medicine. 2019; 2: 64–69 (In Russ.)]. https://dx.doi.org/10.24411/2071-5315-2019-12113.

  46. Peker Y., Glantz H., Eulenburg C. et al. Effect of positive airway pressure on cardiovascular outcomes in coronary artery disease patients with nonsleepy obstructive sleep apnea. Am J Respir Crit Care Med. 2016; 194(5): 613–20. https://dx.doi.org/10.1164/rccm.201601-0088OC.

  47. Bouloukaki I., Giannadaki K., Mermigkis C. et al. Intensive versus standard followup to improve continuous positive airway pressure compliance. Eur Respir J. 2014; 44(5): 1262–74. https://dx.doi.org/10.1183/09031936.00021314.

  48. Wozniak D.R., Lasserson T.J., Smith I. Educational, supportive and behavioural interventions to improve usage of continuous positive airway pressure machines in adults with obstructive sleep apnoea. Cochrane Database Syst Rev. 2014; 1: CD007736. https://dx.doi.org/10.1002/14651858.CD007736.pub2.

  49. Donovan L.M., Patel S.R., Boeder S. et al. New developments in the use of positive airway pressure for obstructive sleep apnea. J Thorac Dis. 2015; 7(8): 1323–42. https://dx.doi.org/10.3978/j.issn.2072-1439.2015.07.30.


About the Autors

Laura Z. Bolieva, MD, professor, head of the Department of pharmacology with clinical pharmacology, North Ossetian State Medical Academy of the Ministry of Healthcare of Russia. Address: 362019, Vladikavkaz, 40 Pushkinskaya Str. E-mail: bolievalz@mail.ru. ORCID: https://orcid.org/0000-0002-1820-7726
Tatyana V. Adasheva, MD, professor, professor of the Department of polyclinic therapy, A.I. Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia. Address: 107150, Moscow, 39 building 1 Losinoostrovskaya Str. E-mail: adashtv@mail.ru. ORCID: https://orcid.org/0000-0002-3763-8994
Andrey G. Malyavin, MD, professor, professor of the Department of phthisiology and pulmonology of the Faculty of general medicine, A.I. Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia. Address: 127473, Moscow, 20 building 1 Delegatskaya Str. E-mail: maliavin@mail.ru
Ekaterina R. Bichenova, part-time postgraduate student at the Department of pharmacology with clinical pharmacology, North Ossetian State Medical Academy of the Ministry of Healthcare of Russia. Address: 362019, Vladikavkaz,
40 Pushkinskaya Str. E-mail: katerinabichenova@gmail.com
Madina D. Daurova, PhD, associate professor of the Department of pharmacology with clinical pharmacology, North Ossetian State Medical Academy of the Ministry of Healthcare of Russia. Address: 362019, Vladikavkaz, 40 Pushkinskaya Str. E-mail: daurovamadina@yandex.ru


Similar Articles

Back to Content

Бионика Медиа